PT-141(Bremelanotide) CAS:189691-06-3

Origin: China
Supply Type: oem service
Processing Time: 10days
Min Order: 99

Quick Details

State	Powder,injection
Color	White
Purity	99%

Supplier Info.

Company Name Beijing Nuoxuan Kangle Biological Science and Technology Co.ltd.
Membership:
Business Type: Manufacturer

Employees Total 5
Annual Revenue US$1 Million - US$2.5 Million

Bremelanotide (tentative brand name Rekynda; former developmental code name PT-141) is a peptide melanocortin receptor agonist which is under development by Palatin Technologies as a treatment for female sexual dysfunction.

In January 2017, Palatin Technologies successfully completed two se III clinical trials of bremelanotide for female sexual dysfunction.The New Drug Application of bremelanotide for female sexual dysfunction was accepted by the FDA in June 2018 with a PDUFA date set for March 23, 2019.